Structure Therapeutics Inc. (GPCR): Total Liabilities
$67.54M
As of 2025-12-31
$71.01M
As of 2026-06-30
+73.2%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.54M | +75.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $38.49M | +32.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $29.05M | +123.3% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $13.01M | n/a | 2024-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | 2025-12-31 | $67.54M | +75.5% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $336.81M | -26.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.36B | -5.5% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.12B | +3.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $899.65M | +5.1% |
Compare GPCR, ACAD, LGND, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗